Enternal formulation

• US 20040067224A1
• Filed: 08/22/2003
• Published: 04/08/2004
• Est. Priority Date: 03/05/2001
• Status: Active Grant

• Current Assignee: Stephen P. Ernest
• Original Assignee: Stephen P. Ernest
• Inventors: Ernest, Stephen P
• Granted Patent: US 6,864,242 B2
• Time in Patent Office: Days
• US Class Current: 424/94.1
• CPC Class Codes: A23L 33/175 Amino acids
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2250/026 Alpha lipoic acid, thioctic acid
• CPC Class Codes: A23V 2250/0606 Arginine
• CPC Class Codes: A23V 2250/062 Glutamine
• CPC Class Codes: A23V 2250/0626 Isoleucine
• CPC Class Codes: A23V 2250/0628 Leucine
• CPC Class Codes: A23V 2250/064 Proline
• CPC Class Codes: A23V 2250/0654 Valine
• CPC Class Codes: A23V 2250/314 Ubiquinone, coenzyme Qn
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals

Abstract

A formulation for enteral administration to a patient is disclosed.

Claims

1. A formulation for enteral administration to a patient, comprising:

from about 1 gram to about 5 grams of Arginine per 240 calories of said formulation;

from about 1.5 grams to about 7.5 grams of glutamine per 240 calories of said formulation;

from about 1 gram to about 5.5 grams of Proline per 240 calories of said formulation; and

from about 2.4 grams to about 9 grams of branched chain amino acids per 240 calories of said formulation.

2. The formulation of claim 1, wherein:

said branched chain amino acids include Leucine, Isoleucine, or Valine.

3. The formulation of claim 1, further comprising:

Pycnogenol.

4. The formulation of claim 1, further comprising:

Alpha-Lipoic acid.

5. The formulation of claim 1, further comprising:

an Oxerutin.

6. The formulation of claim 1, further comprising:

a triterpene glycoside.

7. The formulation of claim 1, further comprising:

Coenzyme Q10.

8. The formulation of claim 1, further comprising:

N-acetyl-cycteine.

9. The formulation of claim 1, further comprising:

a triglyceride containing two residues of the same fatty acid selected from the group consisting of eicosapentaenoic acid or gamma-linolenic acid.

10. A formulation for enteral administration to a patient, comprising:

Pycnogenol, Alpha-Lipoic acid, Oxerutin, a triterpene glycoside, Coenzyme Q10, and N-acetyl-cycteine.

11. The formulation of claim 10, further comprising:

from about 1 gram to about 5 grams of Arginine per 240 calories of said formulation;

from about 1.5 grams to about 7.5 grams of glutamine per 240 calories of said formulation;

from about 1 gram to about 5.5 grams of Proline per 240 calories of said formulation; and

from about 2.4 grams to about 9 grams of branched chain amino acids per 240 calories of said formulation.

12. The formulation of claim 11, wherein:

said branched chain amino acids include Leucine, Isoleucine, or Valine.

13. The formulation of claim 10, further comprising:

a triglyceride containing two residues of the same fatty acid selected from the group consisting of eicosapentaenoic acid or gamma-linolenic acid.

14. A formulation for enteral administration to a patient, comprising:

a first triglyceride containing two eicosapentaenoic acid residues; and

a second triglyceride containing two gamma-linolenic acid residues.

15. The formulation of claim 14, further comprising:

from about 1 gram to about 5 grams of Arginine per 240 calories of said formulation;

from about 1.5 grams to about 7.5 grams of glutamine per 240 calories of said formulation;

from about 1 gram to about 5.5 grams of Proline per 240 calories of said formulation; and

from about 2.4 grams to about 9 grams of branched chain amino acids per 240 calories of said formulation.

16. The formulation of claim 15, wherein:

said branched chain amino acids include Leucine, Isoleucine, or Valine.

17. The formulation of claim 14, further comprising:

Pycnogenol.

18. The formulation of claim 14, further comprising:

Alpha-Lipoic acid.

19. The formulation of claim 14, further comprising:

an Oxerutin.

20. The formulation of claim 14, further comprising:

a triterpene glycoside.

21. The formulation of claim 14, further comprising:

Coenzyme Q10.

22. The formulation of claim 14, further comprising:

N-acetyl-cycteine.